By conjugating the FXI-targeting siRNA with the RIBO-GalSTAR delivery system to achieve a high degree of liver-targeting specificity, RBD4059 demonstrated efficient and durable down-regulation of FXI activity with prolonged activated partial thromboplastin time (APTT) and effects in thrombosis models. Here, F11 is linked to deep vein thrombosis.